Jump Financial LLC Invests $945,000 in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Jump Financial LLC acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 20,867 shares of the company's stock, valued at approximately $945,000.

Several other large investors have also recently modified their holdings of the stock. Barclays PLC boosted its holdings in shares of Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after acquiring an additional 287,243 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Apogee Therapeutics by 13.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company's stock worth $61,390,000 after purchasing an additional 160,822 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Apogee Therapeutics by 11.2% in the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock worth $48,401,000 after buying an additional 82,978 shares during the last quarter. Kennedy Capital Management LLC grew its position in Apogee Therapeutics by 75.5% during the fourth quarter. Kennedy Capital Management LLC now owns 72,307 shares of the company's stock valued at $3,276,000 after buying an additional 31,113 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in Apogee Therapeutics during the fourth quarter valued at approximately $1,099,000. Hedge funds and other institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Stock Down 0.5 %

Apogee Therapeutics stock traded down $0.20 during mid-day trading on Friday, reaching $36.85. 578,730 shares of the company's stock traded hands, compared to its average volume of 511,568. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -15.23 and a beta of 1.72. The stock has a 50 day moving average of $35.11 and a two-hundred day moving average of $42.94.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, sell-side analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Citigroup began coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $92.17.

Insider Activity

In related news, CEO Michael Thomas Henderson sold 10,000 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the transaction, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. The trade was a 0.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the sale, the insider now owns 252,623 shares in the company, valued at approximately $10,279,229.87. The trade was a 1.37 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,970 shares of company stock valued at $1,241,701. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.